Mark Doidge 0:00
So my name is Mark Doidge. I'm the president of headache sciences Incorporated, and we're an AI startup based in Canada. It's always been known that migraine is a brain disease, and since EEG was first discovered, doctors have been searching and looking at the EEG and trying to make sense of it to see if they could find a diagnostic test for migraine. We looked into this, we found that this has been going for 85 years. And basically the EEG signal is probably one of the most complicated signals in the world, and just looking at it, you just can't make sense of it. And so basically the it had to wait for machine learning. Essentially, what we do is the patient would appear at, let's say, an ordinary medical building, and the EEG lab would be manned by a technician, and the technician is not a machine learning specialist. They they would apply the electrodes to the scalp, and then the amplifier would be turned on, and then the brain signals are recorded in the traditional way, and then the signals would then be transmitted to a central signal processing facility where the analysis would be conducted and the algorithms would be applied. After that, a report would be issued by the doctor. So we've raised about 400,000 in cash, and then about 600,000 in kind. And in order for us to get to the next level, we needed 1.5 million US. We don't see a big FDA risk, because EEG is already known to be safe. We don't believe that we have a major market risk because billion people with migraine. So we believe that this whole thing can be quite revolutionary. Migraine is misery, and it's the number two cause of disability in the world, largely because it strikes down women at a relatively young age, when a father hears that his daughter is having some nasty headaches, instead of waiting years, and it's often to get a proper diagnosis and letting the disease percolate, it could receive early intervention. And then the other reasons that over diagnosis or an under diagnosis would would be reduced. So there's an immense benefit to the public. You know, the way the medical world works, and rightly so. They don't want to trust just one small study. They want to see that, you know, additional tests and replication has created a salt has created a solid result. So they're looking for accuracy. And then if that works out, well, then we go into another expanded trial, but knowing that we're in good shape. And then if, if the FDA approves it, then we would, we would begin our release into the North American population and then eventually into other areas of the world. You know, I was a family doctor. If you're a family doctor, pain is a big part of your practice, partly because the patients just keep coming back and back. It's an agonizing part of the medical profession to see that a lot of people continue with a life of pain. And I, like many others before me, it gets under your skin. You just want to do something about it. And so basically, I hit on EEG as being a great avenue, because the signal is very rich in detail. I began on this path alone a long time ago, and there have been ups and downs, but at a certain point it started to come together, where we're starting to get good results. And then we had a big turning point where we were awarded the one and only US Patent, so we have a sweeping US patent. So with those building block blocks in place, I felt there was the basis to really go full out, try to make it into a living, breathing reality. I.
© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
